HK113693A - Improvements in the treatment of tumors in mammals - Google Patents

Improvements in the treatment of tumors in mammals Download PDF

Info

Publication number
HK113693A
HK113693A HK1136/93A HK113693A HK113693A HK 113693 A HK113693 A HK 113693A HK 1136/93 A HK1136/93 A HK 1136/93A HK 113693 A HK113693 A HK 113693A HK 113693 A HK113693 A HK 113693A
Authority
HK
Hong Kong
Prior art keywords
desoxy
amino
difluororibose
purin
compound
Prior art date
Application number
HK1136/93A
Other languages
German (de)
English (en)
French (fr)
Inventor
Gerald Burr Grindey
Larry Wayne Hertel
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27101898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK113693(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HK113693A publication Critical patent/HK113693A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
HK1136/93A 1984-12-04 1993-10-21 Improvements in the treatment of tumors in mammals HK113693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67778384A 1984-12-04 1984-12-04
US78641985A 1985-10-10 1985-10-10

Publications (1)

Publication Number Publication Date
HK113693A true HK113693A (en) 1993-10-29

Family

ID=27101898

Family Applications (1)

Application Number Title Priority Date Filing Date
HK1136/93A HK113693A (en) 1984-12-04 1993-10-21 Improvements in the treatment of tumors in mammals

Country Status (21)

Country Link
US (1) US5464826A (cs)
EP (1) EP0184365B1 (cs)
JP (1) JPH0637394B2 (cs)
KR (2) KR890003439B1 (cs)
CN (1) CN1020194C (cs)
AT (1) ATE92499T1 (cs)
AU (1) AU581269B2 (cs)
CA (1) CA1264738A (cs)
CY (1) CY1806A (cs)
DE (1) DE3587500T2 (cs)
DK (1) DK162965C (cs)
EG (1) EG17765A (cs)
ES (1) ES8801546A1 (cs)
GR (1) GR852858B (cs)
HK (1) HK113693A (cs)
HU (1) HU194273B (cs)
IE (1) IE60328B1 (cs)
IL (1) IL77133A (cs)
NZ (1) NZ214364A (cs)
PH (1) PH23172A (cs)
PT (1) PT81559B (cs)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) * 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
RU1787160C (ru) * 1986-12-24 1993-01-07 Эли Лилли Энд Компани Способ получени иммуноглобулинового конъюгата
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
ES2131152T3 (es) * 1987-08-28 1999-07-16 Lilly Co Eli Procedimiento para aislar selectivamente beta-2'-desoxi-2',2'-difluorocitidina o sus sales.
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
EP0329348B1 (en) * 1988-02-16 1995-07-12 Eli Lilly And Company 2',3'-Dideoxy-2',2'-difluoronucleosides
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
CA2004695C (en) * 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
AU4134793A (en) * 1992-06-22 1993-12-23 Eli Lilly And Company 2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
JP4352115B2 (ja) * 1997-01-24 2009-10-28 クラヴィス・ファルマ・アーエスアー ゲムシタビン誘導体
CA2284263A1 (en) * 1997-03-24 1998-10-01 Eli Lilly And Company Difluoronucleoside phosphonic acids and derivatives thereof
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
EP1189611B1 (en) * 1999-06-14 2006-05-03 Cancer Research Technology Limited Cancer therapy
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0019124D0 (en) * 2000-08-03 2000-09-27 Pfizer Novel process
RU2264389C3 (ru) * 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
US6822001B2 (en) * 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
CA2471509A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
WO2003059339A1 (en) * 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
MXPA04007876A (es) * 2002-02-14 2005-06-20 Pharmasset Ltd Analogos de nucleosido fluorado modificados.
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ATE508747T1 (de) * 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
EP1631258A1 (en) * 2003-05-20 2006-03-08 Aronex Pharmaceuticals Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
DE10323279A1 (de) * 2003-05-21 2004-12-16 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabin-Lösungen
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
CN100450998C (zh) * 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
WO2005076888A2 (en) * 2004-02-06 2005-08-25 Threshold Pharmaceuticals, Inc. Anti-cancer therapies
ES2376484T3 (es) * 2004-04-22 2012-03-14 Eli Lilly And Company Terapia de combinación para el tratamiento del c�?ncer.
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
US20060089329A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solution concentrates
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
CA2586687A1 (en) * 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
MY142304A (en) 2005-01-31 2010-11-15 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound or salt thereof
MX2007010316A (es) * 2005-03-04 2008-02-19 Dabur Pharma Ltd Intermediario de 21-desoxi, 21,21-difluoro-d-ribofuranosil nucleosidos enriquecidos en (-anomero y proceso para prepararlo.
WO2006119347A1 (en) 2005-05-02 2006-11-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
EP1928497A2 (en) * 2005-08-24 2008-06-11 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2007023302A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
WO2007052850A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
CA2652442C (en) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008010571A1 (fr) 2006-07-21 2008-01-24 Taiho Pharmaceutical Co., Ltd. Composé nucléosidique de 2'cyanopyrimidine
CA2658917C (en) 2006-07-24 2014-10-21 Taiho Pharmaceutical Co., Ltd. 3'-ethynylcytidine derivative
EP2065372B1 (en) * 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
JP2010510243A (ja) * 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) * 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US8193339B2 (en) 2007-11-06 2012-06-05 Pharmaessentia Corp. Synthesis of β-nucleosides
EP2217611B1 (en) * 2007-11-07 2013-07-31 Merck Sharp & Dohme Corp. Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN108434151A (zh) 2008-01-11 2018-08-24 里亚塔医药公司 合成三萜类化合物及用以治病之方法
EP2248804A4 (en) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
BRPI0911208B1 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals, Inc Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica
DK2271658T3 (en) 2008-04-18 2017-02-06 Reata Pharmaceuticals Inc ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGED OLEANOLIC ACID DERIVATIVES
EP2279196B1 (en) 2008-04-18 2015-01-21 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CA2724550C (en) 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
US8314137B2 (en) * 2008-07-22 2012-11-20 Trustess Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
CA2757743C (en) * 2009-04-06 2017-10-10 Eisai Inc. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepin-2-0ne derivatives for treating cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
AR076263A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Composiciones y metodos para tratar cancer. uso.
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
US9192680B2 (en) 2010-06-01 2015-11-24 Aposense Ltd. Pharmaceutical compounds
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2012123889A1 (en) 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
MY179607A (en) 2011-04-01 2020-11-11 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
KR101809858B1 (ko) 2012-04-04 2017-12-15 할로자임, 아이엔씨 항-히알루로난 제제 및 종양-표적 탁산을 이용한 병용 치료
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
SG11201407537YA (en) 2012-06-08 2014-12-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
KR102090849B1 (ko) 2012-07-04 2020-03-19 에프. 호프만-라 로슈 아게 공유 결합된 항원-항체 접합체
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2015191563A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin c
WO2015197736A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR102705821B1 (ko) 2015-06-16 2024-09-12 가부시키가이샤 프리즘 바이오랩 항암제
CN106317147B (zh) * 2015-07-06 2018-11-27 扬州硒瑞恩生物医药科技有限公司 核苷类化合物及其制备方法
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
JP2019523778A (ja) 2016-06-29 2019-08-29 イーライ リリー アンド カンパニー 膵癌の治療に使用するための、ｅｒｋ１／２阻害剤化合物と、ゲムシタビン、またはゲムシタビンおよびｎａｂ−パクリタキセルとの併用
EP3541404A1 (en) 2016-11-21 2019-09-25 Bexion Pharmaceuticals, Inc. A combination therapy including sapc-dops for the treatment of pancreatic cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
BR112019014127A2 (pt) 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. Composição farmacêutica para tratamento de tumores
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3664844A1 (en) 2017-08-07 2020-06-17 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
CN111565744B (zh) 2017-09-18 2024-12-31 加利福尼亚大学董事会 紧密连接蛋白6抗体和治疗癌症的方法
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
AU2019296174B2 (en) 2018-06-29 2021-10-07 Changchun Changcheng Pharmaceutical Technology Co., LTD Phosphorus-containing prodrugs of gemcitabine
US20220031670A1 (en) 2018-09-20 2022-02-03 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
EP3908261A1 (en) 2019-01-11 2021-11-17 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
EP3941944A4 (en) 2019-03-20 2022-11-30 The Regents of the University of California Claudin-6 bispecific antibodies
PL3941946T3 (pl) 2019-03-20 2025-05-26 The Regents Of The University Of California Przeciwciała klaudyny-6 i koniugat lekowy
MX2021013271A (es) 2019-04-30 2022-01-06 Inst De Medicina Molecular Joao Lobo Antunes Inhibidores de la via rank en combinacion con inhibidores de cdk.
EP3980541A1 (en) 2019-06-04 2022-04-13 Apterna Limited Aptamers against transferrin receptor (tfr)
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
CN110684062B (zh) * 2019-10-18 2022-12-13 大连大学 一种治疗非小细胞肺癌的药物及其制备方法
GB202019692D0 (en) 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (cs) *
US3705147A (en) * 1969-08-22 1972-12-05 Univ Utah 3-deazapyrimidine nucleosides and method of preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
JPS5136467A (en) * 1974-09-20 1976-03-27 Tanabe Seiyaku Co 11 beetaa dd2** harogeno 2** deokishiribofuranoshirurashirujudotai no seiho
DE2628202A1 (de) * 1976-06-23 1977-12-29 Max Planck Gesellschaft Verfahren zur herstellung von 2'-substituierten-d-ribofuranosylpurinderivaten
US4058602A (en) * 1976-08-09 1977-11-15 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類

Also Published As

Publication number Publication date
EG17765A (en) 1990-08-30
AU581269B2 (en) 1989-02-16
IE853038L (en) 1986-06-04
ES549547A0 (es) 1987-08-01
DE3587500T2 (de) 1993-12-16
DK162965C (da) 1992-06-01
JPH0637394B2 (ja) 1994-05-18
CN1020194C (zh) 1993-03-31
CY1806A (en) 1995-09-08
JPS61148193A (ja) 1986-07-05
EP0184365A3 (en) 1988-01-27
EP0184365B1 (en) 1993-08-04
HUT39188A (en) 1986-08-28
CA1264738A (en) 1990-01-23
AU5055585A (en) 1986-06-12
ATE92499T1 (de) 1993-08-15
DE3587500D1 (de) 1993-09-09
PH23172A (en) 1989-05-19
HU194273B (en) 1988-01-28
ES8801546A1 (es) 1987-08-01
DK549685A (da) 1986-06-05
IL77133A (en) 1991-01-31
GR852858B (cs) 1986-03-28
NZ214364A (en) 1988-11-29
PT81559A (en) 1985-12-01
EP0184365A2 (en) 1986-06-11
US5464826A (en) 1995-11-07
IE60328B1 (en) 1994-06-29
KR890003426B1 (ko) 1989-09-20
CN85109409A (zh) 1986-08-27
KR860004920A (ko) 1986-07-16
PT81559B (pt) 1988-03-03
KR890003439B1 (ko) 1989-09-21
DK162965B (da) 1992-01-06
DK549685D0 (da) 1985-11-28

Similar Documents

Publication Publication Date Title
EP0184365B1 (en) Improvements in the treatment of tumors in mammals
EP1030857B1 (en) Adenosine a1 receptor agonists
EP0269574B1 (en) Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
CA1295998C (en) Nucleosides and their use as antineoplastic agents
US4071680A (en) 5'-Deoxy-5-fluoropyrimidine nucleosides
EP0376518B1 (en) Phospholipid nucleosides
HU203363B (en) Process for producing 2',3'-dideoxy-2',2'-difluoronucleosides and pharmaceutical compositions comprising same as active ingredient
US5661136A (en) 2-halo-2'-fluoro ARA adenosines as antinoplastic agents
JPH0662663B2 (ja) デスアザプリン―ヌクレオシド―誘導体
KR20160145542A (ko) 인플루엔자 rna 복제의 저해제로서의 4''-다이플루오로메틸 치환된 뉴클레오사이드 유도체
US5061793A (en) 2-deoxy-2',2'-difluoro-inosine and 5'O-derivatives
EP0222192A2 (en) Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil
EP0535231A1 (en) Pyrimidine nucleoside derivative
EP2675278B1 (en) Methods for synthesizing molybdopterin precursor z derivatives
AU4061193A (en) Novel adenosine derivatives
JP2017057200A (ja) 抗ｄｎａウィルス活性などの生理活性を有するヌクレオシド誘導体
US5153180A (en) Fluorinated nucleosides and process for treating retrovirus infections therewith
Komiotis et al. Biologically Important Nucleosides: A General Method for the Synthesis of Unsaturated Ketonucleosides of Uracil and its Analogs
EP0366171B1 (en) Nucleoside derivatives
US5644043A (en) 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
US5034380A (en) Alkoxymethylidene epipodophyllotoxin glucosides
EP0095292A1 (en) 5-(2-halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections"
JPH0717671B2 (ja) 新規な５−フルオロ−２′−デオキシウリジン誘導体およびその塩
MXPA06010863A (en) 4'-c-substituted 2-haloadenosine derivative

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20051124